Clinical Trial Detail

NCT ID NCT02608684
Title A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Cedars-Sinai Medical Center
Indications

fallopian tube carcinoma

ovarian carcinoma

peritoneal carcinoma

Therapies

Cisplatin + Gemcitabine + Pembrolizumab

Age Groups: adult

No variant requirements are available.